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Abstract 
 Patients with diabetes have a high prevalence of thyroid disease 
compared with non-diabetic population. In the case of type 1 diabetes, it is 
often associated with autoimmune endocrine and systemic diseases as: 
Graves-Basedow disease, autoimmune chonic thyroiditis (ACT), Addison's 
disease, celiac disease, pernicious anemia, myasthenia gravis, vitiligo, etc.. 
The purpose of this study is to determine the main aspects of humoral 
immunity in a group of children with type 1 diabetes and thyroid disorders. 
The studied group was represented by 83 cases (71 girls and 12 boys), aged 
between 7-17 years. They were used clinical, imaging, biochemical, hormonal 
and immunological parameters. Results: Prevalence of positive anthyroid 
antibodies (ACAT) in the study group was: Basedow – Graves disease – 100% 
(both),  ACT - 85.18%  antiTPO and 83.33% antiTg, euthyroid difusse goiter 
– 0% (both). In the case of children and adolescents with type 1 diabetes and 
ACT with positive antiTPO AB we notice that they had a younger onset age 
of diabetes (4.86 ± 3.94 vs. 8.62 ± 0.51 years), a longer duration of diabetes 
(9.23 ± 4.05 vs. 8.12 ± 0.64 years), elevated HbA1c values (8.91 ± 2.03 vs.7, 
55 ± 1.96%) and lower TSH values (12.00 ± 23.7 vs. 14.77 ± 17.03 mIU/ml) 
than those negative. Conclusions: It is recommended determination of 
antithyroid antibodies, particularly those antiTPO in children and adolescents 
with type 1 diabetes at onset of diabetes, or before puberty and, if they are 
positive should be tested the thyroid function annually to minimize the risk of 
undiagnosed hypothyroidism. 
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Introduction  
 Patients with diabetes have a high prevalence of thyroid disease 
compared with non-diabetic population. In the case of type 1 diabetes, it is 
often associated with autoimmune endocrine and systemic diseases as: 
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Graves-Basedow disease, Hashimoto thyroiditis, Addison's disease, celiac 
disease, pernicious anemia, myasthenia gravis, vitiligo, etc.. A particular 
association of type 1 diabetes with hypo-or hyperthyroidism is characteristic 
to autoimmune polyglandular syndrome (APS). 
 One of the prominent features of the APS is the presence of circulating 
autoantibodies to autoantigens normally present in the endocrine organs 
involved in the disease. Such autoantibodies can occur long before the 
appearance of the evident clinical diseases and are thus predictive of the 
possible onset of autoimmune disease later in life. Patients with any one of the 
two types of APS may have autoantibodies against the same antigens. The 
identification of circulating organ-specific autoantibodies provided the earliest 
and strongest evidence for the autoimmune pathogenesis of the APS 
(Aldasouqi et al, 2006).  
 Autoantibodies in patients with APS react with thyroid gland proteins, 
including thyroid peroxidase, thyroglobulin, and thyrotropin receptors (El 
Rehewy et al, 1981). While immunoglobulins against the thyrotropin receptor 
may stimulate or inhibit both thyroid gland activity and growth, no 
consistently discernible effect on thyroid function has yet been attributed to 
autoantibodies that recognize thyroid peroxidase or thyroglobulin 
Autoimmunity against the thyroid gland is distinctly unusual in APS-1, but is 
frequent in APS-2a and -2b. Children with GAD antibody positivity in 
particular have been demonstrated to have a higher risk for the development 
of anti-thyroid antibodies (Bonifacio et al, 2009). 
 An important responsibility for the clinician managing patients with 
single endocrine autoimmunity diseases is to determine those patients’ risk for 
the occurrence of polyglandular disorders. Clues uncovered by a thorough 
history and physical examination may reveal the true multi-focal nature of a 
patient's condition (Aldasouqi et al, 2006).  
 Subclinical or "compensated" deficiencies, identified by elevations of 
tropic hormones (e.g., normal thyroxine but elevated TSH in Hashimoto's 
disease), reflect early gland destruction that may be detected during the 
evaluation of more overt disease in other glands. Once recognized, each 
individual hormone deficiency should be treated and monitored using the same 
therapeutic replacement regimens as those used for patients who have isolated 
gland dysfunction (Aldasouqi et al, 2006).  
 Suggested screening protocol is:for Addison’s Disease evaluation of 
ACTH, electrolytes, morning cortisol, aldosterone level, DHEA-S; 
adrenocortical, steroidal cell or 21-hydroxylase autoantibodies with the 
frequency annual, antibody levels at time of diagnosis, for alopecia physical 
exam annual, for autoimmune thyroid disease thyroid function tests and 
antibody levels annual, for celiac disease tissue transglutaminase (tTG) – IgA 
levels, biopsies as needed annual, for pernicious anemia antiparietal cell 
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antibody levels, CBC, vitamin B12 every 5 years, for primary hypogonadism 
luteinizing and follicular stimulating hormone levels, estradiol or testosterone 
annual, for type 1 diabetes (T1DM) hemoglobin A1c, fasting glucose, 
autoantibodies (Eg, GAD-65, IA-2, and IAA) annual, antibody levels at time 
of diagnosis and every 3 to 5 years (Aldasouqi et al, 2006).  
 Family members of a proband with T1DM or APS 2a/2b should 
undergo focused history, exam and screening every three to five years with 
T1DM autoantibody levels, TSH, serum B12, and anti-adrenal antibody levels 
(Aldasouqi et al, 2006).  
 If a patient is found to have thyroiditis, family members should also be 
screened for thyroid autoantibodies and goiter also. 
 The key to successfully managing patients with an autoimmune 
endocrinopathy is to identify and treat their autoimmunities before they cause 
significant morbidity and mortality. The treatment of organ insufficiencies is 
identical whether it occurs in isolation or as part of an APS. Endocrine 
replacement therapy remains the cornerstone of their clinical management. 
Patient education about the nature of the disease is often critical to the early 
recognition of additional new autoimmunities, and as with any chronic 
diseases, individualized needs for psychosocial support must be assessed. 
Genetic counseling is also warranted and family members should be screened 
with the use of specific tests (Aldasouqi et al, 2006).  
 Systematic studies of the long-term prognosis in APS patients are 
lacking, but clinical impressions are that the APS-2 patients have rates of 
morbidity and mortality that are identical to those of the component diseases 
when they occur in isolation. Adrenal crises are still a significant cause of 
preventable mortality, and uncontrolled thyroid hormone imbalances can 
rarely present as emergencies, especially in the elderly. The complications of 
T1DM, both acute and chronic, are as important in the APS setting as in 
isolated pancreatic disease (Aldasouqi et al, 2006).  
  
Material and method 
Investigated population 
 The group of children was represented by 83 subjects aged between 7-
17 years. 
 All children from the study group had type 1 diabetes. 
 In the studied group, the gender distribution of the children was 5.9 / 
1, represented by 71 girls (85.54%) and 12 boys (14.45%). 
 
  
European Scientific Journal December 2016 edition vol.12, No.36 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
21 
Methods of investigation  
 The methods of investigation were represented by clinical data - case 
history, current status, imagistic- thyroid ultrasound, biochemical - for 
glycemic balance: fasting blood glucose, glycosylated hemoglobin, 
investigation of the thyroid gland: TSH, FT4, FT3, thyroid antibodies. 
 Determination of plasma glucose was performed by enzyme 
technique with glucosooxidasis. Normal values were taken between 70 - 110 
mg%; diabetes mellitus - values equal or over 126 mg%, impaired glucose 
tolerance - values between 110 - 125 mg% and the OGTT at 2 h between 140 
- 200 mg% and impaired fasting glucose - values between 110 - 125 mg% and 
OGTT at 2 h under 140 mg%.  
 Determination of HbA1c was achieved through the DiaStat for 
measuring HbA1c reported to the total HbA.  
 To determine the TSH level in plasma, the free fraction of 
triiodotironin (FT3), and the plasma free fraction of thyroxin (FT4) were 
performed a quantitative method ARCHITECT; witch is an immunological 
method, Chemilumnescent Microparticle Immunoassay (CMIA). Normal 
values were following: TSH = 0.465-4.68 Miu/ml, FT3 = 3.69 -10.4 pmol/l, 
FT4 = 10-28.2 pmol/l.  
 The immunological parameters were represented by autoimmune 
thyroid markers - antibodies (antiTPO and antiTg antibodies).  
 To determine serum levels of antiTPO antibodies it was used the kit 
AxSYM antiTPO, an immunological method (Microparticle Enzyme 
Immunoassay) (MEIA). Normal values:  antiTPO antibodies <35 IU/ml.  
 To determine serum levels of antiTg antibodies it was used the kit 
AxSYM antiTg, a MEIA method as well (Microparticle Enzyme 
Immunoassay). Normal values: antiTg antibodies <55 IU/ml.  
 Thyroid ultrasound was performed in all cases and allowed us to 
measure thyroid volume, thyroid study and the changes in parenchyma’s 
density.  
 An increased density, uniform, characterizes normal thyroid 
parenchyma easily distinguished from the neck muscles that are hypo dens.  
 Inflammatory processes and autoimmune pathology appears hypo 
dens.  The scale was assessed as being discreet +, moderate ++ and marked 
+++.  
 In the autoimmune thyroid disease the parenchyma of the gland 
appears hypo dens.  
 Chronic autoimmune thyroid disorder appears with a hypoecogenity of 
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Results and discussion 
 Thyroid humoral immunity was assessed by measuring serum 
antiperoxidase (antiTPO AB) and antithyreoglobulin (antiTg AB) antibodies 
titres in whole lot patients. 
 Prevalence of positive anthyroid antibodies titer changes in the study 
group was for Basedow – Graves disease – 100% (both AB), for ACT - 
85.18%  antiTPO AB and 83.33% antiTg AB and for euthyroid difusse goiter 
– 0% (both AB).  
 The incidence of antithyroid antibodies in patients with type 1 diabetes 
varies from one author to another, and it is estimated between 7-40% 
(Marginean et al, 2000). Percentage variability may occur due to different 
methods of investigation and study group homogeneity (ethnic differences, 
gender and age). The incidence of antithyroid antibodies is estimated at 20-
30% in North America and at 6.3 to 14.2% in Western Europe [Marginean et 
al, 2000]. 
 By gender, antithyroid antibodies are frequently found at the girls 
compared with boys (Marginean et al, 2000). 
 In patients with ACT, antithyreoglobulin antibody positivity occurs in 
50% of patients, while the antiperoxidase antibody positivity in 90% of them 
(Marginean et al, 2000). 
 A study in Germany shows that between 3-50% of patients with type 
1 diabetes have positive antithyroid antibodies (ACAT) (Umpierrez et al, 
2003). Another study in Germany shows that the prevalence of antithyroid 
antibodies increases with age, the highest prevalence being between 15-20 
years (16.9% antiTPO AB and 12.8% for antiTg AB) (Kordonouri, 2002). 
 This is supported by another study in Germany which shows that the 
raised ACAT prevalence is 3.7% in those under 5 years and reach over 25.3% 
of those aged 15-20 years (Holl, 1999). 
 The higher value of antiTPO AB was found in patients with Graves-
Basedow disease (1000 ± 0 mIU/ml) and the lowest in patients with euthyroid 
diffuse goiter (8.05 ± 7.29). In the case ACT, the medium value was 416.11 ± 
319.11 mIU/ml. 
 Regarding antiTPO AB, in our group we obtained the results shown in 
Table 1. 








(n = 4) 
ACT 
(n = 54) 
Euthyroid 
difusse goiter 
(n = 25) 
n % n % n % n % 
Higher 50 60.24 4 100 46 85.18 - - 
Normal 33 39.76 - - 8 14.81 25 100 
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 A study in Poland showed that raised antithyroid antibodies were 
present in 17.8% of children, at those who these were present were older, and 
insulin requirements did not differ between those with positive and negative 
ACAT (Czerniawska et al, 2003). 
 A study in Germany on 216 patients with a mean age of 12.9 years has 
shown that raised antiTPO antibodies were present in 10% of cases, antiTg 
antibodies in 8.7% and both in 5.9% cases (Kordonouri, 2002). 
 Another study conducted in Spain indicate that the children with 
positive ACAT were older and had higher levels of TSH to those with negative 
ACAT (Lopez Medina et al, 2004). 
Table 2. Comparative data (p) between cases antiTPO AB positive and negative in patients 
with ACT from the study group 





Cases number (%) 8 (8 F) 46 (7 M şi 39 F) < 0.001 
Age (years) 16.75 ± 0.46 14.06 ± 2.37 < 0.001 
Onset age of DM (years) 8.62 ± 0.51 4.86 ± 3.94 < 0.001 
DM duration (years) 8.12 ± 0.64 9.23 ± 4.05 0.087 
BMI (kg/m2) 19.72 ± 1.57 20.79 ± 2.82 0.14 
HbA1c (%) 7.55 ± 1.96 8.91 ± 2.03 0.10 
Glycemia (mg%) 183.75 ± 90.09 149.67 ± 59.2 0.33 
TSH (mIU/ml) 14.77 ± 17.03 12.00 ± 23.7 0.69 
FT4 (pmol/l) 13.5 ± 10.1 7.59 ± 6.57 0.15 
 
 In the case of children and adolescents with type 1 diabetes and ACT 
with positive antiTPO AB we notice that they had a younger onset age of 
diabetes (4.86 ± 3.94 vs. 8.62 ± 0.51 years), a longer duration of diabetes (9.23 
± 4.05 vs. 8.12 ± 0.64 years), elevated HbA1c values (8.91 ± 2.03 vs.7, 55 ± 
1.96%) and lower TSH values (12.00 ± 23.7 vs. 14.77 ± 17.03 mIU/ml) than 
those with negative antiTPO AB (Table 2). 
 All 8 cases with negative antiTPO AB were under treatment with 
thyroid hormones for ~ 1-2 years. It is possible that at onset these cases 
presented subclinical hypothyroidism and positive antiTPO AB. After 
treatment was obtain the balance of thyroid status and negative antiTPO AB, 
but with raised antiTg AB persistence. 
 The incidence of positive antiTg AB titres was the same as for antiTPO 
antibodies. In the case of ACT, 45 cases present antiTg antibodies raised 
(Table 3). 
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(n = 83) 
Graves-Basedow 
disease 
(n = 4) 
ACT 
(n = 54) 
Euthyroid 
difusse goiter 
(n = 25) 
n % n % n % n % 
Higher 49 59.03 4 100 45 83.33 - - 
Normal 34 40.97 - - 9 16.66 25 100 
 
 In the entire group of children, both antithyroid antibodies were 
present in 49 subjects. In patients with Graves-Basedow disease, all 4 patients 
had both antibodies raised, and in those with ACT, 45 subjects had both 
antibodies raised. 
 In Europe have been numerous studies on the prevalence of antiTPO 
AB in children with various thyroid diseases such as: 
  UK: study on 65 patients with Hashimoto's thyroiditis and on 38 
patients with Graves-Basedow disease showed that antiTPO antibodies were 
positive in 86% of those with Hashimoto's thyroiditis and 87% of Graves-
Basedow disease: ifn the case of antiTg antibodies, the proportion of positive 
results was much lower, 58% and 73% (Gilmour et al, 2000) 
  Serbia: antiTPO antibodies were positive in almost all patients with 
Hashimoto's thyroiditis and 75% of patients with Graves-Basedow disease 
(Trbojevic et al, 2005) 
  France: antiTPO antibodies were present in 40.5% of patients with 
Hashimoto thyroiditis and 34.6% of Graves-Basedow disease (Estienne et al, 
1999) 
  Germany: from 659 patients, 15.4% had elevated antiTPO AB  and 
14.4% antiTg AB, girls were more affected than boys (Kordonouri et al, 2005) 
  Poland: on a sample of 219 children and adolescents, the authors 
found higher titre of antiTPO AB in 34.7% of cases, also predominantly in 
females (Kalicka-Kasperczyk et al, 2003) 
 In our study, regarding the presence of ACAT, significant differences 
were found between their titres in patients with Graves-Basedow disease and 
ACT (autoimmune diseases) than those with diffuse euthyroid goiter (Table 
4). 
 A study in Germany shows that 8 of 16 patients with positive ACAT 
showed elevated TSH after 2-6 years (median 3.5 years). Therefore the authors 
recommended that annual TSH determination in patients with positive ACAT. 
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Table 4. Prevalence of ACAT in the group of children of adolescent 
Thyroid disease AntiTPO AB significant 
titers 
AntiTg AB significant 
titers 
n % n % 
Graves-Basedow disease 4 100% 4 100% 
ACT 46 85.18% 45 83.33% 
Euthyroid difusse goiter - - - - 
 
 Also, German Society of Pediatrics recommends that patients with 
positive ACAT, with increased thyroid volume and with hypoecogen typical 
aspect at thyroid ultrasound to be treated with L-thyroxine (Kordonouri et al, 
2003). 
 Contradictory results show an U.S. study that recommends to test first 
TSH and then ACAT. The authors show that did not receive any benefit from 
the treatment of patients with normal TSH values (Hoffman et al, 2003). 
 Annual determination of TSH in patients with type 1 diabetes for early 
identification of thyroid dysfunction is supported by other studies (Ditta et al, 
2001). 
 Depending on age groups, we obtained the following results in patients 
with ACT regarding ACAT (Table 5). 
Table 5. ACAT titer by age in patients with ACT 
Age n AntiTPO AB AtiTg AB 
7-9 years 2 802.5 ± 928.36 518.4 ± 681.08 
10-14 years 21 632.74 ± 192.00 911.38 ± 226.31 
15-17 years 31 244.45 ± 230.99 402.05 ± 314.89 
 
 We obtained significant differences in the amount of ACAT between 
the age groups 10-14 years and 15-17 years (p <0.001), values being higher in 
the age group 10-14 years (puberty) to age group 15 to 17 years (adolescence). 
 Following study and correlation of data referred to 54 cases were found 
morphofunctional different forms of thyroid disease (Table 6). 
 Highest incidence was owned by ACT with eutiroidism, detected in 28 
patients. Of these, 15 cases presented with goiter and 13 cases eutiroidism 
eutiroidism without goiter (asymptomatic). 
 ACT with hypothyroidism was diagnosed in 26 patients. A total of 18 
subjects were presented ACT with hypothyroidism and goiter and 8 subjects 
ACT with hypothyroidism without goitre. Also, 8 subjects had subclinical 
hypothyroidism and 18 subjects clinical hypothyroidism. 
 Basedow disease was present in 4 cases (1 with and 3 without goiter 
goiter). 
 Goiter was present in 25 cases, all 25 cases were euthyroid. 
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(n = 4) 
Euthyroid diffuse 
goiter (n =25) 
 n % n % n % 
Hypothyroidism 26 48.14 - - - - 
- with goiter 18 69.23 - - - - 
- without goiter 8 30.77 - - - - 
Euthyroidism 28 51.85 - - 25 100 
- with goiter 15 53.57 - - 25 100 
- without goiter 13 46.43 - - - - 
Hyperthyroidism - - 4 100 - - 
- with goiter - - 1 25 - - 
- without goiter - - 3 75 - - 
 
 In the case of ACT, depending on the clinical form, we obtained two 
groups: 
 - ACT with hypothyroidism 
 - ACT with eutiroidism 
 In each group we appreciated the onset age of diabetes, current age, 
diabetes duration, BMI and sex. There were no significant differences in these 
parameters in the 2 groups (Table 7 and 8). 
 Euthyroid ACT was present in 28 cases (51.85%), predominantly in 
girls - 25 cases (89.28%). At diagnosis, mean age of type 1 diabetes was 7.96 
± 3.75 years. 
 Hashimoto ACT with hypothyroidism was present in 26 cases 
(48.15%), gender distribution is F/M = 22/4, the average age of type 1 diabetes 
was 10.26 ± 3.44 years, so superior circumstance prior. 
Table 7. Comparative data (p) between ACT with and without 
hypothyroidism in the studied children group 
 
  
Parameters ACT with 
hypothyroidism 
(n = 26) 
ACT with 
euthyroidism 










BMI (kg/m2) 21.4 ± 2.62 19.92 ± 2.59 0.04 
antiTPO AB 373.47 ± 285.54 455.72 ± 347.88 0.34 
Onset age of DM 
type  1 (years) 
4.53 ± 3.69 6.25 ± 3.93 0.10 
Current age (years) 14.73 ± 2.01 14.21 ± 2.72 0.42 
DM type 1 duration 
(years) 
10.26 ± 3.44 7.96 ± 3.75 0.02 
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Table 8. Characteristics of different forms of ACT in the studied group of children and 
adolescents with type 1 diabetes 
Characteristics ACT with hypothyroidism ACT with euthyroidism 
Without 
goiter 
With goiter Without 
goiter 
With goiter 
Cases number 8 18 13 15 
Male 0 4 0 3 
Female 8 14 13 12 





Onset age of DM 
(years) 
5.62 ± 3.11 4.05 ± 3.9 4.84 ± 
2.88 
7.46 ± 4.38 
DM duration 
(years) 
8.62 ± 0.91 11 ± 3.91 9.07 ± 
2.49 
7 ± 4.44 
 
 A study in Italy on 160 children, 43 boys and 117 girls, mean age of 
9.1 ± 3.6 years, with Hashimoto's thyroiditis, showed that the presence of 
goiter and antiTg AB raised in onset, together with increased AntiTPO AB 
and TSH, are predictors for the subsequent appearance of hypothyroidism 
(Kalicka-Kasperczyk et al, 2003). 
 In a study conducted in Germany showed that the antiTPO antibody 
prevalence increases with age (Kordonouri et al, 2002). In a recent study, 
Jaeger et al. (2001) showed a significant increase of antiTPO AB titres with 
recent onset of diabetes (Kordonouri et al, 2003). Other studies have shown 
that females are more prone to autoimmune thyroid  disease at any age 
(Kordonouri et al, 2002). 
 It is also shows that the subjects with the antibody antiTPO positive or 
both positive ACAT have significantly elevated levels of TSH, 
hypoechogenity and increase in volume of the thyroid gland (Kordonouri et 
al, 2002). 
 Padberg et al. (2001) confirms that those with the antiTPO antibody 
positive have elevated levels of TSH, they are more sensitive than antiTg 
antibodies to diagnose autoimmune thyroid disease (Hoffman, 2003). 
 In a German study only 10.5% of patients with autoimmune thyroid 
damage were treated with L-thyroxine. This reflects the contradictory 
discussions of literature concerning the effectiveness of therapy in euthyroid 
patients with thyroid hormones (TSH and FT4 concentrations of normal) and 
in patients with subclinical hypothyroidism (elevated TSH concentration and 
normal FT4) (Hoffman, 2003, Ditta et al, 2001). 
 Rother et al. (1994) showed that most children and adolescents with 
normal FT4 not respond to replacement therapy by reducing goiter, even if they 
have normal or elevated TSH levels (Kordonouri et al, 2002). On the other 
hand, Padberg et al. (2001) show a significant reduction in levels of TSH and 
antiTPO AB in euthyroid patients with thyroid autoimmune disease after 1 
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year of treatment with L-thyroxine, compared with those untreated (Ditta et 
al, 2001). 
 Engler et al. (1992) estimated the risk of clinical hypothyroidism after 
10 years to 63% in patients with increased TSH and positive antiTPO AB, 
compared with 22% in those with isolated increase in TSH. Chase et al. 
reported reduced growth rate in children with diabetes and subclinical 
hypothyroidism, especially for TSH values above 50 mU/L. After the 
treatment with L-thyroxine was found to increase during the prepubertal 
growth. The German study reported no significant differences in terms of 
glycemic control in the 2 groups and the growth rate (Kordonouri et al, 2002). 
 Other studies have shown the association of celiac disease with type 1 
diabetes and autoimmune thyroid disease (Jaeger et al, 2001, Padberg et al, 
2001). Diabetic patients with autoimmune thyroid damage with or without 
antithyroid antibodies do not appear to have a high prevalence of celiac disease 
(Cooper, 2001, Meloni et al, 2001). 
 
Conclusion 
 In conclusion, there seems to be an inherent tendency to develop an 
autoimmune response against specific molecules of target organs in the 
majority of immunologically mediated endocrine diseases. The inheritance 
pattern of these diseases aids in the diagnosis of autoimmune disorders such 
as APS-1, T1DM and Addison's disease before progression to clinical onset in 
first-degree relatives of affected individuals. The diagnostic approach for these 
autoimmune mediated endocrine diseases is then based on genetic 
ascertainments, but can be complemented by the detection of a combination 
of immunologic markers with high predictive value. 
 The immunological markers for thyroid diseases are antiTPO and 
antiTg AB, the most important and usefull being determination of antiTPO 
AB.  
 However, it is recommended determination of antithyroid antibodies, 
particularly those antiTPO in children and adolescents with type 1 diabetes at 
onset of diabetes, or before puberty. In the case of positive antibodies should 
be tested the thyroid function (annually) and perform thyroid ultrasound to 
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